FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

ABT

Abbott LaboratoriesNYSE · Health Care Equipment · Health Care
Previous close
106.20
Change
+1.63 / +1.56%
FinDog View
Neutral
52-Week Range ?
81.97 – 132.03
P/E (TTM) ?
39.1
Sector median 29.5
Forward P/E ?
17.6
Based on consensus earnings for the next 12 months
Market Cap
$184B
1M
+7.46%
S&P 500 −0.91% over same period
Volume / Avg Volume
8.4M / 10.3M
0.82× average
Latest earnings analysisFY2026 Q2Reported 2026-07-16

Abbott Q2 2026: sales up 13.0%, adjusted EPS $1.31, guidance raised

Abbott's 13.0% reported sales growth is mostly the Exact Sciences deal, not the base business — comparable growth was 4.8%. Adjusted EPS of $1.31 squeaked past the $1.2922 consensus, and management raised the full-year adjusted EPS range to $5.45–$5.60. The catch: getting from 4.8% to the guided 6.5%–7.5% comparable growth needs a much stronger second half.

Read the full analysis →
Revenue$12.59BYoY +13.00%
EPS (non-GAAP)$1.31Beatest. $1.29
Next-day move+1.87%

Price History

Closing price · USD1M6M1Y5Y
80100120140160EEEEEE2021-102023-012024-042025-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 31.31M6M1Y5Y
10203040502023-052024-032025-022025-122026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2027-01-20
in 80 days · After hours
Consensus EPS
$1.66
Last quarter EPS $1.31
Avg. next-day move over the last 6 reports
±1.6%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 99 of its 5-year rangeExpensive
5-year range 15.7 – 37.7 · Median 31.3
Last 4 quarters: $793M in buybacks + $4.2B in dividends, 2.71% of market cap combined
P/E (TTM)
39.1
P/B
3.6
P/S
3.8
Dividend Yield
1.98%
Earnings Reaction
Over the last 6 reports, the stock moved ±1.6% on average on the first trading day after, rising 4 times
Most recent +1.87%
Volatility & Correlation
1-year beta -0.03 · Correlation with S&P 500 -0.01Low beta
Annualized volatility 27% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 3 · $46.9MNet selling $46.9M
  • 09-02MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERSell$0.00M27 shares · Avg price 109.54
  • 08-25Ford Robert BCHAIRMAN AND CEOSell$46.2M398,832 shares · 2 trades · Avg price 115.85
  • 08-11Morrone Louis H.EXECUTIVE VICE PRESIDENTSell$0.64M5,850 shares · Avg price 109.83
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q111.16+7.8%56.2%1.351.080.920.61
FY2025 Q411.46+4.4%57.0%2.251.782.631.01
FY2025 Q311.37+6.9%55.4%2.061.642.290.94
FY2025 Q211.14+7.4%56.4%2.051.781.551.01
FY2025 Q110.36+4.0%56.9%1.691.330.930.76
FY2024 Q410.97+7.2%55.0%1.919.232.155.26
FY2024 Q310.64+4.9%55.8%1.861.652.150.94
FY2024 Q210.38+4.0%55.6%1.671.301.430.74
FY2024 Q19.96+2.2%55.2%1.391.230.630.70
FY2023 Q410.24+1.5%55.5%1.781.592.280.91
FY2023 Q310.14−2.6%54.6%1.651.441.320.82
FY2023 Q29.98−11.4%55.1%1.541.380.700.78

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView